Expert Directory

Saad Z. Usmani, MBBS, MD, MBA, FACP, FRCP, FASCO

    Chief, Myeloma Service
    Member, Myeloma, Cellular Therapy, and Adult BMT Services
    Memorial Sloan Kettering Cancer Center
    Professor, Clinical Medicine
    Weill Cornell Medical College, Cornell University
    New York, NY

Saad Z. Usmani, MBBS, MD, MBA, FACP, FRCP, FASCO, joined Memorial Sloan Kettering Cancer Center in 2021 as chief of myeloma service and holds a faculty position as professor of clinical medicine at Weill Cornell Medical College, Cornell University.


Dr Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed his residency in internal medicine at DMC Sinai-Grace Hospital/Wayne State University in Detroit, MI, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington. In 2010, he joined the University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy in Little Rock as director of developmental therapeutics. In 2013, he was recruited to the Atrium Health Levine Cancer Institute as the inaugural division chief of plasma cell disorders and director of clinical research for hematologic malignancies, where he built an internationally renowned multiple myeloma program.


He is board-certified in internal medicine, medical oncology, and hematology. Dr Usmani is a fellow of the American College of Physicians, the Royal College of Physicians (in the United Kingdom), and the American Society of Clinical Oncology (ASCO). He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group, the Alliance Myeloma Committee (chair), the American Society of Hematology (ASH), ASCO, the International Myeloma Society (IMS; board member), the American Society for Transplantation and Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. Dr Usmani has also served as vice chair of the SWOG Barlogie-Salmon Myeloma Committee, as chair of the ASH Scientific Committee on Plasma Cell Neoplasia, and on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders.


Dr Usmani has received several international awards and honors in recognition of his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research in Hematology, the Multiple Myeloma Excellence in Clinical Research Award (COMy Congress), the Leukemia & Lymphoma Society (LLS) Scholar in Clinical Research Award, the IMS Bart Barlogie Clinical Investigator Award in Clinical and Translational Research, and the LLS Career Development Program Achievement Award.


Active in clinical and translational research, Dr Usmani has research interests that focus on plasma cell disorders—in particular, high-risk multiple myeloma. He has led the clinical development of several novel therapies, including anti-CD38 monoclonal antibodies, bispecific antibodies, and CAR T-cell therapies, resulting in regulatory approvals in multiple myeloma. Dr Usmani has authored/coauthored more than 295 peer-reviewed research manuscripts in The New England Journal of Medicine , The Lancet , the Journal of Clinical Oncology , Cancer Cell , Blood , and Leukemia , among others.


Contributing Articles

No related "post" posts found.